Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On May 18, 2023, at the 2023 Annual Meeting of Stockholders (the "Annual Meeting") of Fulgent Genetics, Inc. (the "Company"), the Company's stockholders voted to approve the amendment and restatement of the Company's 2016 Omnibus Incentive Plan (the "Amended Plan") increasing the number of shares of common stock reserved for issuance thereunder by 3 million shares.

The Amended Plan is described in further detail in the Company's definitive proxy statement on Schedule 14A for the Annual Meeting filed with the Securities and Exchange Commission (the "SEC") on March 31, 2023 (the "Proxy Statement"), which description is incorporated herein by reference. The complete text of the Incentive Plan is set forth in Exhibit 10.1 to this Form 8-K and is incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 18, 2023 at 9:00 a.m. Pacific Standard Time, the Company held its Annual Meeting at the Company's offices at 4399 Santa Anita Avenue, El Monte, California 91731. Of the Company's 29,692,195 shares of common stock issued and outstanding and eligible to vote as of the record date of March 23, 2023, a quorum of 23,914,817 shares, or approximately 81% of the eligible shares, was present in person or represented by proxy. Each of the matters set forth below is described in detail in the Company's Proxy Statement. The following actions were taken at the Annual Meeting:

Proposal 1



Election of the following nominees as directors of the Company, each to serve
until the 2024 Annual Meeting and until his or her successor is duly elected and
qualified.

                          Votes For        Votes Withheld       Broker Non-Vote
Ming Hsieh                 19,263,232              328,280             4,323,305
Michael Nohaile, Ph.D.     18,992,081              599,431             4,323,305
Regina Groves              19,316,955              274,557             4,323,305
Linda Marsh                12,574,024            7,017,488             4,323,305


Proposal 2

Ratification of the selection of Deloitte & Touche LLP as the Company's
independent registered public accounting firm for the year ending December 31,
2023.

 Votes For        Votes Against       Votes Abstained      Broker Non-Vote
  23,754,565             130,264                29,988                   -


Proposal 3

Approval, on a non-binding advisory basis, the compensation of our named executive officers.



 Votes For        Votes Against       Votes Abstained       Broker Non-Vote
  18,882,872             607,633               101,007             4,323,305


Proposal 4

Approval of an amendment and restatement of the Company's 2016 Omnibus Incentive Plan increasing the number of shares of common stock reserved for issuance thereunder by 3 million shares.



 Votes For        Votes Against       Votes Abstained       Broker Non-Vote
  10,762,154           8,732,947                96,411             4,323,305





--------------------------------------------------------------------------------

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.



 Exhibit
   No.      Description
10.1+         Amended and Restated 2016 Omnibus Incentive Plan of the
            Registrant.
104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document)

+Management compensation plan or arrangement.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses